These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4789495)

  • 21. [Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa].
    Ambrosetto C; Martinelli P
    Minerva Med; 1971 Oct; 62(82):4017-9. PubMed ID: 5125069
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
    Pohlmeier H; Schön I; Matussek N
    Arzneimittelforschung; 1970 Jul; 20(7):932-3. PubMed ID: 4918920
    [No Abstract]   [Full Text] [Related]  

  • 23. [The addition of amantadine to prolonged treatment with L-Dopa. Considerations on 20 cases].
    Giuffrè R; Gambacorta D
    Minerva Med; 1971 Oct; 62(82):4009-12. PubMed ID: 5125066
    [No Abstract]   [Full Text] [Related]  

  • 24. The treatment of parkinsonism with L-Dopa and amantadine.
    Green J
    J Fla Med Assoc; 1970 Jun; 57(6):28-33. PubMed ID: 5445813
    [No Abstract]   [Full Text] [Related]  

  • 25. [6 months of treatment with amantadine and L-Dopa. Comparison in 2 groups of patients with parkinsonism].
    Buscaino GA; Campanella G; Zallone E
    Minerva Med; 1971 Oct; 62(82):3974-8. PubMed ID: 5125057
    [No Abstract]   [Full Text] [Related]  

  • 26. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
    Danielczyk W; Korten JJ
    Med Monatsschr; 1971 Oct; 25(10):472-9. PubMed ID: 5122447
    [No Abstract]   [Full Text] [Related]  

  • 27. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
    Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

  • 29. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.
    Eltayb A; Wadenberg ML; Svensson TH
    Biol Psychiatry; 2005 Aug; 58(4):337-43. PubMed ID: 16102547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combined (surgical and drug) therapy of parkinsonism].
    Kandel' EI; Iadgarov IS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(8):1157-61. PubMed ID: 6388198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa].
    Ferraris M
    Minerva Med; 1971 Oct; 62(82):3971-3. PubMed ID: 5125056
    [No Abstract]   [Full Text] [Related]  

  • 32. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine].
    Sigwald J; Raymondeaud C; Piot C
    Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718
    [No Abstract]   [Full Text] [Related]  

  • 33. L-dopa and benserazide in the treatment of acute hepatic encephalopathy in infancy.
    Sinniah D; Chan LL
    Singapore Med J; 1980 Aug; 21(4):658-60. PubMed ID: 7221579
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
    Kamenetskiĭ VK
    Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
    [No Abstract]   [Full Text] [Related]  

  • 35. [On the palm-chin reflex in parkinsonian patients treated with L-adamantyl-amine hydrochloride (amantadine)].
    Loria G; D'Arrigo G; Di Stefano F
    Riv Neurobiol; 1971; 17(3):379-87. PubMed ID: 5156133
    [No Abstract]   [Full Text] [Related]  

  • 36. L-dopa and amantadine for Parkinsonism.
    Drug Ther Bull; 1970 Aug; 8(17):65-7. PubMed ID: 5480244
    [No Abstract]   [Full Text] [Related]  

  • 37. Reversible effect of L-dopa on tremor and catatonia induced by alpha-methyl-p-tyrosine.
    Bédard P; Larochelle L; Poirier LJ; Sourkes TL
    Can J Physiol Pharmacol; 1970 Jan; 48(1):82-4. PubMed ID: 4984213
    [No Abstract]   [Full Text] [Related]  

  • 38. L-dopa and amantadine hydrochloride in extra-pyramidal disorders.
    Parkes JD; Knill-Jones RP; Clements PJ
    Postgrad Med J; 1971 Feb; 47(544):116-9. PubMed ID: 5572526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Amantadine hydrochloride in the treatment of Parkinson's syndrome].
    De la Herrán J; Figuerido JA
    Rev Esp Otoneurooftalmol Neurocir; 1971; 29(167):45-9. PubMed ID: 5091472
    [No Abstract]   [Full Text] [Related]  

  • 40. [Results obtained with L-DOPA and amantadine in the treatment of patients with disorders of consciousness and of the vigilant state].
    Paini GP; Passoni M
    Ateneo Parmense Acta Biomed; 1973 Sep; 44(5):353-9. PubMed ID: 4794006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.